<DOC>
	<DOCNO>NCT02206295</DOCNO>
	<brief_summary>The primary aim study demonstrate bioequivalence rate extent absorption 1600 μg selexipag test drug ( administer orally film-coated tablet 1600 μg , twice day ( b.i.d . ) 1600 μg selexipag reference drug ( administer orally 8 film-coated tablet 200 μg b.i.d . ) steady-state healthy male subject follow multiple-dose up-titration scheme .</brief_summary>
	<brief_title>Study Healthy Male Subjects Demonstrate Bioequivalence 1600 μg Selexipag Administered Eight Tablets 200 μg Single Tablet 1600 μg</brief_title>
	<detailed_description />
	<mesh_term>Selexipag</mesh_term>
	<criteria>Signed informed consent local language prior studymandated procedure . Healthy male subject age 18 55 year ( inclusive ) Screening . No clinically significant finding physical examination Screening . Body mass index 18.0 30.0 kg/m^2 ( inclusive ) Screening . Systolic blood pressure 100145 mmHg , diastolic blood pressure 5090 mmHg , pulse rate 4590 beat per minute ( inclusive ) , measure Screening . 12lead electrocardiogram without clinically relevant abnormality , measure Screening . Hematology , clinical chemistry , urinalysis test result deviate normal range clinically relevant extent Screening . Negative result urine drug screen alcohol breath test Screening . Ability communicate well investigator , local language , understand comply requirement study . Known allergic reaction hypersensitivity selexipag excipient drug formulation use study . History clinical evidence disease and/or existence surgical medical condition , might interfere absorption , distribution , metabolism , excretion selexipag . Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . Veins unsuitable intravenous puncture either arm ( e.g. , vein difficult locate , access puncture ; vein tendency rupture puncture ) . Treatment selexipag another investigational drug within 1 month prior Screening 5 halflives , whichever longer . History clinical evidence alcoholism drug abuse within 3year period prior Screening . Excessive caffeine consumption Screening . Smoking within 3 month prior Screening inability refrain smoke course study . Previous treatment prescribe medication ( include vaccine ) overthecounter medication within 2 week prior first study drug administration . Loss 500 mL blood within 3 month prior Screening . Positive result hepatitis serology ( hepatitis B antigen hepatitis C antibody ) , except vaccinated subject subject past resolve hepatitis , Screening . Positive result human immunodeficiency virus serology Screening . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol . Legal incapacity limit legal capacity Screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>selexipag</keyword>
	<keyword>ACT-333679</keyword>
</DOC>